Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$314.97 -2.4%	$300.06	$205.87 ▼ $333.70	$41.07B	0.23	856,314 shs	648,031 shs
BMRN BioMarin Pharmaceutical	$58.16 -1.1%	$57.51	$52.93 ▼ $94.85	$11.15B	0.17	1.75 million shs	1.29 million shs
GMAB Genmab A/S	$21.40 -2.1%	$21.04	$17.24 ▼ $28.56	$13.73B	0.94	1.25 million shs	937,253 shs
GNMSF Genmab A/S	$214.95 +1.1%	$208.09	$170.00 ▼ $292.80	$14.20B	0.91	2,562 shs	2 shs
UCBJF UCB	$203.85	$183.05	$149.85 ▼ $209.66	$38.53B	0.47	517 shs	221 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+0.55%	-2.80%	+6.67%	+35.69%	+25.17%
BMRN BioMarin Pharmaceutical	-1.42%	+2.74%	+2.33%	+3.52%	-28.52%
GMAB Genmab A/S	+1.30%	+7.10%	-4.29%	+16.21%	-14.97%
GNMSF Genmab A/S	-1.14%	+7.07%	-2.56%	+16.43%	-14.99%
UCBJF UCB	0.00%	+2.01%	+6.49%	+35.27%	+54.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.1558 of 5 stars	2.4	4.0	0.0	4.3	2.8	2.5	0.6
BMRN BioMarin Pharmaceutical	4.9459 of 5 stars	3.4	3.0	0.0	3.3	2.8	2.5	4.4
GMAB Genmab A/S	4.1797 of 5 stars	3.3	5.0	0.0	0.0	3.4	0.0	3.1
GNMSF Genmab A/S	0.8422 of 5 stars	0.0	3.0	0.0	0.0	2.2	0.0	1.3
UCBJF UCB	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.80	Moderate Buy	$345.70	9.76% Upside
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$93.61	60.96% Upside
GMAB Genmab A/S	2.67	Moderate Buy	$37.80	76.68% Upside
GNMSF Genmab A/S	0.00	N/A	N/A	N/A
UCBJF UCB	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest BMRN, GNMSF, UCBJF, GMAB, and ALNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$364.00 ➝ $404.00
7/11/2025	ALNY Alnylam Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$336.00 ➝ $359.00
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
7/7/2025	ALNY Alnylam Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$328.00 ➝ $384.00
7/3/2025	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$97.00
6/30/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$287.00 ➝ $333.00
6/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$320.00 ➝ $377.00
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/23/2025	UCBJF UCB	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Overweight
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
5/5/2025	BMRN BioMarin Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$124.00 ➝ $104.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.27	N/A	N/A	$0.52 per share	605.70
BMRN BioMarin Pharmaceutical	$2.85B	3.91	$3.16 per share	18.38	$29.69 per share	1.96
GMAB Genmab A/S	$3.12B	4.40	$1.50 per share	14.23	$8.04 per share	2.66
GNMSF Genmab A/S	$3.12B	4.55	$15.18 per share	14.16	$80.53 per share	2.67
UCBJF UCB	$5.27B	7.32	$8.76 per share	23.28	$50.52 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	353.89	N/A	-11.49%	-510.31%	-6.48%	8/7/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$426.86M	$2.69	21.62	13.34	0.82	17.76%	11.34%	8.95%	8/4/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.76	12.16	12.02	6.56	35.11%	18.08%	14.52%	8/14/2025 (Estimated)
GNMSF Genmab A/S	$1.14B	$17.63	12.19	∞	N/A	35.11%	19.23%	15.44%	8/7/2025 (Estimated)
UCBJF UCB	$371.23M	N/A	0.00	28.87	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)

Latest BMRN, GNMSF, UCBJF, GMAB, and ALNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ALNY Alnylam Pharmaceuticals	-$0.0538	N/A	N/A	N/A	$633.54 million	N/A
8/4/2025	Q2 2025	BMRN BioMarin Pharmaceutical	$1.02	N/A	N/A	N/A	$761.51 million	N/A
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/8/2025	Q1 2025	GNMSF Genmab A/S	$1.88	$3.05	+$1.17	$3.05	$761.09 million	$765.14 million
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
GNMSF Genmab A/S	N/A	N/A	N/A	N/A	N/A
UCBJF UCB	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
BMRN BioMarin Pharmaceutical	0.10	5.52	3.49
GMAB Genmab A/S	N/A	5.34	5.32
GNMSF Genmab A/S	N/A	5.34	5.32
UCBJF UCB	0.33	1.19	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BMRN BioMarin Pharmaceutical	98.71%
GMAB Genmab A/S	7.07%
GNMSF Genmab A/S	N/A
UCBJF UCB	N/A

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
BMRN BioMarin Pharmaceutical	0.85%
GMAB Genmab A/S	1.54%
GNMSF Genmab A/S	1.54%
UCBJF UCB	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.43 million	Optionable
BMRN BioMarin Pharmaceutical	3,040	191.78 million	190.15 million	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
GNMSF Genmab A/S	2,682	66.07 million	65.06 million	Not Optionable
UCBJF UCB	9,083	189.02 million	N/A	Not Optionable

BMRN, GNMSF, UCBJF, GMAB, and ALNY Headlines

Recent News About These Companies

UCB (OTCMKTS:UCBJF) Shares Gap Down - Here's Why

July 10 at 4:04 PM | marketbeat.com

UCB (OTCMKTS:UCBJF) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?

July 4, 2025 | marketbeat.com

UCB (OTCMKTS:UCBJF) Shares Gap Down - Should You Sell?

June 30, 2025 | marketbeat.com

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

May 20, 2025 | finance.yahoo.com

United Community Banks, Inc. (UCB) Q1 2025 Earnings Call Transcript

April 22, 2025 | seekingalpha.com

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

April 3, 2025 | finance.yahoo.com

UCB Convening Notice to the General Meeting of the Shareholders 2025

March 21, 2025 | finance.yahoo.com

UCB price target raised to EUR 220 from EUR 130 at Berenberg

February 25, 2025 | markets.businessinsider.com

UCB price target raised to EUR 200 from EUR 105 at Morgan Stanley

February 12, 2025 | markets.businessinsider.com

UCB assumed with an Equal Weight at Morgan Stanley

February 12, 2025 | markets.businessinsider.com

UCB SA (0NZT) Receives a Hold from Kepler Capital

February 2, 2025 | markets.businessinsider.com

UCB SA (0NZT) Gets a Buy from Barclays

January 27, 2025 | markets.businessinsider.com

United Community Banks, Inc. (UCB) Q4 2024 Earnings Call Transcript

January 22, 2025 | seekingalpha.com

UCB SA (0NZT) Receives a Buy from Barclays

January 16, 2025 | markets.businessinsider.com

UCB price target raised to EUR 215 from EUR 200 at Deutsche Bank

November 12, 2024 | markets.businessinsider.com

UBS Remains a Buy on UCB SA (0NZT)

November 4, 2024 | markets.businessinsider.com

Artisan Global Equity Fund Q3 2024 Commentary

October 25, 2024 | seekingalpha.com

Artisan International Fund Q3 2024 Commentary

October 25, 2024 | seekingalpha.com

Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy

October 18, 2024 | seekingalpha.com

Barclays Keeps Their Buy Rating on UCB SA (0NZT)

October 7, 2024 | markets.businessinsider.com

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

September 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN, GNMSF, UCBJF, GMAB, and ALNY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$314.96 -7.68 (-2.38%)

Closing price 03:58 PM Eastern

Extended Trading

$314.32 -0.65 (-0.21%)

As of 04:10 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$58.16 -0.67 (-1.13%)

Closing price 03:58 PM Eastern

Extended Trading

$58.11 -0.05 (-0.08%)

As of 04:07 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Genmab A/S NASDAQ:GMAB

$21.40 -0.47 (-2.13%)

Closing price 03:58 PM Eastern

Extended Trading

$21.45 +0.05 (+0.26%)

As of 04:11 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S OTCMKTS:GNMSF

$214.95 +2.40 (+1.13%)

As of 11:55 AM Eastern

UCB OTCMKTS:UCBJF

$203.85 0.00 (0.00%)

As of 03:35 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time